GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit
GT Biopharma (NASDAQ: GTBP) announced its participation in the 10th Anniversary of the Innate Killer Summit in San Diego from March 3-5, 2025. Dr. Jeffrey Miller from the University of Minnesota Medical School will present as an expert speaker, discussing tri-specific engagers' mechanisms in enhancing NK cell activity.
The company's second-generation TriKE®, GTB-3650, is currently in a Phase 1 dose escalation study for patients with hematological malignancies. The trial will evaluate:
- Up to 14 patients across seven cohorts
- Focus on relapsed or refractory CD33 expressing hematologic malignancies
- Including refractory acute myeloid leukemia (AML)
- High-risk myelodysplastic syndrome (MDS)
Enrollment is progressing as planned, with initial data expected in 2025. The trial is registered on clinicaltrials.gov under identifier NCT06594445.
GT Biopharma (NASDAQ: GTBP) ha annunciato la sua partecipazione al 10° Anniversario del Summit degli Innate Killer a San Diego dal 3 al 5 marzo 2025. Il Dr. Jeffrey Miller della Scuola di Medicina dell'Università del Minnesota sarà presente come relatore esperto, discutendo i meccanismi degli engagers tri-specifici nel potenziare l'attività delle cellule NK.
Il TriKE® di seconda generazione dell'azienda, GTB-3650, è attualmente in uno studio di escalation della dose di Fase 1 per pazienti con neoplasie ematologiche. Lo studio valuterà:
- Fino a 14 pazienti suddivisi in sette coorti
- Focus su neoplasie ematologiche CD33 positive in recidiva o refrattarie
- Inclusa la leucemia mieloide acuta refrattaria (AML)
- Sindrome mielodisplastica ad alto rischio (MDS)
L'arruolamento sta procedendo come previsto, con i dati iniziali attesi nel 2025. Lo studio è registrato su clinicaltrials.gov con l'identificativo NCT06594445.
GT Biopharma (NASDAQ: GTBP) anunció su participación en el 10º Aniversario de la Cumbre de Innate Killer en San Diego del 3 al 5 de marzo de 2025. El Dr. Jeffrey Miller de la Escuela de Medicina de la Universidad de Minnesota será el orador experto, discutiendo los mecanismos de los engagers tri-específicos para mejorar la actividad de las células NK.
El TriKE® de segunda generación de la compañía, GTB-3650, se encuentra actualmente en un estudio de escalada de dosis de Fase 1 para pacientes con malignidades hematológicas. El ensayo evaluará:
- Hasta 14 pacientes en siete cohortes
- Enfoque en malignidades hematológicas CD33 positivas en recaída o refractarias
- Incluyendo leucemia mieloide aguda refractaria (AML)
- Síndrome mielodisplásico de alto riesgo (MDS)
La inscripción avanza según lo planeado, con datos iniciales esperados para 2025. El ensayo está registrado en clinicaltrials.gov bajo el identificador NCT06594445.
GT Biopharma (NASDAQ: GTBP)는 2025년 3월 3일부터 5일까지 샌디에고에서 열리는 제10회 인내 살상자 서밋 기념행사에 참여한다고 발표했습니다. 미네소타 대학교 의과대학의 제프리 밀러 박사가 전문가 연사로 발표하며, NK 세포 활동을 향상시키는 삼중 특이성 결합제의 메커니즘에 대해 논의할 예정입니다.
회사의 2세대 TriKE®, GTB-3650는 현재 1상 용량 상승 연구 중이며, 혈액 악성 종양 환자를 대상으로 하고 있습니다. 이 시험은 다음을 평가할 것입니다:
- 7개 코호트에 걸쳐 최대 14명 환자
- 재발 또는 저항성 CD33 발현 혈액 악성 종양에 초점
- 저항성 급성 골수성 백혈병(AML) 포함
- 고위험 골수형성이상증후군(MDS)
등록은 계획대로 진행 중이며, 초기 데이터는 2025년에 예상됩니다. 이 시험은 clinicaltrials.gov에 NCT06594445 식별자로 등록되어 있습니다.
GT Biopharma (NASDAQ: GTBP) a annoncé sa participation au 10ème Anniversaire du Sommet des Innate Killer à San Diego du 3 au 5 mars 2025. Le Dr. Jeffrey Miller de l'École de Médecine de l'Université du Minnesota interviendra en tant qu'expert, discutant des mécanismes des engageurs tri-spécifiques pour améliorer l'activité des cellules NK.
Le TriKE® de deuxième génération de l'entreprise, GTB-3650, est actuellement en étude d'escalade de dose de Phase 1 pour des patients atteints de malignités hématologiques. L'essai évaluera :
- Jusqu'à 14 patients répartis sur sept cohortes
- Concentration sur les malignités hématologiques exprimant CD33 en rechute ou réfractaires
- Incluant la leucémie myéloïde aiguë réfractaire (AML)
- Syndrome myélodysplasique à haut risque (MDS)
Le recrutement progresse comme prévu, avec des données initiales attendues en 2025. L'essai est enregistré sur clinicaltrials.gov sous l'identifiant NCT06594445.
GT Biopharma (NASDAQ: GTBP) gab seine Teilnahme am 10. Jubiläum des Innate Killer Summit in San Diego vom 3. bis 5. März 2025 bekannt. Dr. Jeffrey Miller von der medizinischen Fakultät der Universität Minnesota wird als Experte sprechen und die Mechanismen der tri-spezifischen Engager zur Verbesserung der NK-Zellaktivität erörtern.
Das Zweigenerationen TriKE® des Unternehmens, GTB-3650, befindet sich derzeit in einer Phase-1-Dosiserhöhungsstudie für Patienten mit hämatologischen Malignomen. Die Studie wird folgende Punkte bewerten:
- Bis zu 14 Patienten in sieben Kohorten
- Fokus auf rezidivierenden oder refraktären CD33-exprimierenden hämatologischen Malignomen
- Einbeziehung von refraktärer akuter myeloischer Leukämie (AML)
- Hochrisiko-myelodysplastisches Syndrom (MDS)
Die Rekrutierung verläuft wie geplant, und erste Daten werden für 2025 erwartet. Die Studie ist unter clinicaltrials.gov mit der Identifikationsnummer NCT06594445 registriert.
- None.
- None.
SAN FRANCISCO, CALIFORNIA, March 04, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced that Jeffrey Miller, MD1 from the University of Minnesota Medical School2 will participate as an expert speaker at the 10th Anniversary of the Innate Killer Summit being held March 3-5, 2025 in San Diego, CA.
10th Anniversary of the Innate Killer Summit
| Title: | Showcasing Advantages of Tri-Specific Killer Engagers to Turbocharge NK Recruitment & Potency |
| Date: | Tuesday, March 4, 2025 |
| Time: | 1:30 pm PT |
| Participant: | Dr. Jeffrey Miller, MD, Deputy Director, Masonic Cancer Center, Co-Leader Immunology Program at the University of Minnesota Medical School & Consulting Senior Medical Director, GT Biopharma |
Dr. Miller will speak to the mechanisms by which tri-specific engagers enhance NK cell activity, their unique ability to work synergistically with NK cells to improve cytotoxicity and increase cytokine release, and the preclinical and clinical data shown to date.
GTB-3650, GT Biopharma’s wholly owned second-generation TriKE, is currently being evaluated in a Phase 1 dose escalation study in patients with hematological malignancies. Enrollment is proceeding as expected, marking consistent advancement in the trial which will evaluate GTB-3650 in up to approximately 14 patients (seven cohorts) with relapsed or refractory (r/r) CD33 expressing hematologic malignancies, including refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). The company anticipates sharing initial data from the study in 2025. More details can be found on clinicaltrials.gov with the identifier: NCT06594445.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell engager platform. Our TriKE® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology. For more information, please visit gtbiopharma.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.
TriKE® is a registered trademark owned by GT Biopharma, Inc.
Investor Relations Contact:
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
212-915-2577
1 Dr. Miller is the Consulting Senior Medical Director at GT Biopharma and holds stock and options in GTBP.
2 The University of Minnesota, pursuant to its license agreement with GT Biopharma, is entitled to receive royalties should commercial sales of GTB-3650 be realized. This interest has been reviewed and managed by the University of Minnesota in accordance with its conflict of interest policies.
FAQ
What is the current status of GT Biopharma's GTB-3650 clinical trial?
How many patients will be enrolled in GTBP's Phase 1 trial for GTB-3650?
What types of cancer is GT Biopharma's GTB-3650 targeting?
When will GT Biopharma (GTBP) release initial data from the GTB-3650 trial?
What is the clinical trial identifier for GT Biopharma's GTB-3650 study?
